Patents by Inventor Noubar B. Afeyan

Noubar B. Afeyan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160193299
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Application
    Filed: March 22, 2016
    Publication date: July 7, 2016
    Inventors: Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Noubar B. Afeyan, Pedro Valencia, Jason P. Schrum
  • Publication number: 20160158295
    Abstract: Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 9, 2016
    Inventors: Noubar B. Afeyan, Mary-Jane Lombardo McKenzie, Kevin Daniel Litcofsky, David N. Cook, Matthew R. Henn, Geoffrey von Maltzahn
  • Publication number: 20160158294
    Abstract: Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 9, 2016
    Inventors: Geoffrey Von Maltzahn, Matthew R. Henn, David N. Cook, David Arthur Berry, Noubar B. Afeyan, Brian Goodman, Mary-Jane Lombardo McKenzie, Marin Vulic
  • Publication number: 20160143961
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
    Type: Application
    Filed: December 14, 2015
    Publication date: May 26, 2016
    Inventors: David Berry, Shaila Rahman, Noubar B. Afeyan, Johanne Kaplan, Neal Gordon
  • Publication number: 20160024171
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Application
    Filed: October 8, 2015
    Publication date: January 28, 2016
    Inventors: Jason P. Schrum, Stephane Bancel, Noubar B. Afeyan, Kenechi Ejebe
  • Publication number: 20160024141
    Abstract: The current landscape for preparative chromatographic RNA purification uses reversed phase HPLC, but this technique presents many issues with process scale up and ion exchange for preparative purification has only been used for short RNAs. The invention provides preparative purification of RNA (e.g., mRNA) using ion (e.g., anion) exchange chromatography that allows for separation of longer RNAs up to 10,000 nucleotides in length via a scalable method. This method avoids problems with current techniques by using low pressure chromatography that is agreeable with existing equipment in cGMP commercial facilities, that uses aqueous-bases solutions as the mobile phase (rather than flammable of greater than 10 mg RNA/mL resin (e.g., using larger pore sorbents, >500 Angstroms, that display greater mRNA binding capacities), and that yields desired RNA salt forms for downstream formulation with no additional manipulation necessary (unlike ion pair reverse phase techniques).
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: Modema Therapeutics, Inc.
    Inventors: William Joseph ISSA, Joseph Louis BARBERIO, John Grant AUNINS, Noubar B. AFEYAN
  • Patent number: 9181319
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: November 10, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Jason P. Schrum, Stephane Bancel, Noubar B. Afeyan
  • Publication number: 20150306212
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: June 12, 2015
    Publication date: October 29, 2015
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Publication number: 20150190435
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 9, 2015
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David Arthur Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20150182588
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: December 23, 2014
    Publication date: July 2, 2015
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Patent number: 9028841
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 12, 2015
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20140371302
    Abstract: This invention relates to modified nucleic acid compositions encoding cell-penetrating polypeptides to provoke an innate immune response in a cell and methods of delivering protein-binding partners to target cells.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 18, 2014
    Inventors: Noubar B. Afeyan, Gregory J. Sieczkiewicz
  • Patent number: 8906668
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: December 9, 2014
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Patent number: 8822663
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 2, 2014
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Jason P. Schrum, Stéphane Bancel, Noubar B. Afeyan
  • Publication number: 20140243399
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Application
    Filed: May 6, 2014
    Publication date: August 28, 2014
    Applicant: Moderna Therapeutics, Inc.
    Inventors: Jason P. Schrum, Stephane Bancel, Noubar B. Afeyan
  • Publication number: 20140206752
    Abstract: Provided are formulations, compositions, kits and methods for delivering biological moieties such as modified nucleic acids into cells to induce, reduce or modulate protein expression in non-human vertebrates.
    Type: Application
    Filed: May 16, 2012
    Publication date: July 24, 2014
    Applicant: MODERNA THERAPEUTICS, INC.
    Inventors: Noubar B. Afeyan, Gregory Sieczkiewicz, Stephane Bancel
  • Publication number: 20140199281
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: March 20, 2014
    Publication date: July 17, 2014
    Applicant: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20140147454
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Application
    Filed: October 2, 2013
    Publication date: May 29, 2014
    Applicant: MODERNA THERAPEUTICS, INC.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin de Fougerolles, Noubar B. Afeyan
  • Publication number: 20140147425
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 29, 2014
    Applicant: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Patent number: 8710200
    Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: April 29, 2014
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Jason P. Schrum, Noubar B. Afeyan, Gregory J. Sieczkiewicz, Stephane Bancel, Antonin de Fougerolles, Sayda M. Elbashir